Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Back to alerts
EMCURENSEEmcure Pharmaceuticals Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Wed, 4 Feb, 2026 · 14:22 IST

Re-appointment of three Independent Directors for second term

Management Changes View source PDFExplain this filing

EMCURE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+1.5%Reaction day
₹1510.00
prior close
₹1518.00
announcement price
In-mkt
timing
Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.8%+0.7% vs market
Pharmaceuticals peers, median of 155sector+0.2%+1.2% vs sector

On the reaction day the stock moved 0.7 pts more than Nifty Smallcap 250 and 1.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.2
10m
+0.0
15m
+0.0
30m
+1.3
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+1.5+0.8+0.7+0.2+1.2
Next day
-1.8-0.3-1.5-0.4-1.4
2d
+0.1-0.6+0.7-1.1+1.3
3d
+2.5+1.9+0.6+0.7+1.9
4d
+0.1+2.4-2.4+1.3-1.3
5d
-1.0+2.6-3.5+1.5-2.4
1w
-1.7+0.2-1.8+0.3-2.0
15d
-5.6+0.5-6.1-2.3-3.4
1m
-2.3-4.5+2.1-5.1+2.8
2m
+2.5-6.8+9.3-7.9+10.5
3m
+19.1+5.8+13.3+0.7+18.4
UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Emcure Pharmaceuticals board has approved the re-appointment of three Independent Directors for a second consecutive term, subject to shareholder approval. Dr. Shailesh Kripalu Ayyangar re-appointed for 5 years from June 2, 2026. Mr. Vijay Keshav Gokhale for 5 years from April 16, 2026. Dr. Vidya Rajiv Yeravdekar for 3 years from April 16, 2026. All three have been directors since April 16, 2021. None are debarred by SEBI and none are related to existing directors or KMPs.

Likely market impact

Routine board continuity, no change in management. Subject to shareholder approval at the next general meeting.